A Comparative Clinical Study of Prophylatic Effect of Intravesical Instillation with Thiotepa and Mitomycin C after TUR for Superficial Bladder Tumor.
- Author:
Jun CHEON
1
;
Jae Heung CHO
Author Information
1. Korea University College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
thiotepa;
mitomycin C;
bladder tumor;
chemotherapy
- MeSH:
Administration, Intravesical*;
Cost Savings;
Cross-Over Studies;
Drug Therapy;
Exanthema;
Humans;
Mitomycin*;
Prospective Studies;
Recurrence;
Thiotepa*;
Urinary Bladder Neoplasms*;
Urinary Bladder*
- From:Korean Journal of Urology
1988;29(1):23-28
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
In a prospective study without crossover design, we were to compare the efficacy of Thiotepa and Mitomycin C when each was instilled intravesically after complete transurethral resection of all visible superficial bladder cancer(stage Ta, Tis and Tl) in 89 consecutive patients. The 3-months and 1year rates free of recurrence were 85.7 and 82.1 percent, respectively for Thiotepa(28 patients), 86.4 and 81.8 percent for Mitomycin C(22 patients), and 79.5 and 56.4 percent for control group(39 patients). Although Thiotepa intravesical instillation demonstrated effectiveness slightly superior to that of Mitomycin C, no significance difference in recurrence and progression rate was noted for either drug group. No patient required discontinuation of therapy in either group because of toxicity although 3 patients required temporary discontinuation of therapy secondary to myelosuppression (2) and symptomatic cystitis(1) in Thiotepa group, and 5 patients secondary to symptomatic cystitis(3) and rash or contact dermatitis(2) in mitomycin C group. This results suggest that Thiotepa is more useful and effective than Mitomycin C for the prophylactic treatment of superficial bladder tumor in cost saving, acceptable toxicity and patients`s convenience, in addition to decreasing the recurrence rate.
